Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Free Report) has received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $51.00.

A number of brokerages have recently issued reports on ARWR. Morgan Stanley dropped their price target on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a research report on Monday, May 13th. Citigroup boosted their target price on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 10th. Royal Bank of Canada reissued an “outperform” rating and set a $50.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Finally, HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, May 13th.

View Our Latest Research Report on Arrowhead Pharmaceuticals

Insider Buying and Selling

In related news, Director Hongbo Lu bought 1,000 shares of the company’s stock in a transaction on Monday, March 18th. The shares were acquired at an average cost of $27.49 per share, with a total value of $27,490.00. Following the completion of the acquisition, the director now owns 31,680 shares of the company’s stock, valued at approximately $870,883.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $35.19, for a total value of $1,407,600.00. Following the transaction, the chief financial officer now owns 400,600 shares of the company’s stock, valued at $14,097,114. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Hongbo Lu purchased 1,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, March 18th. The stock was bought at an average price of $27.49 per share, with a total value of $27,490.00. Following the transaction, the director now owns 31,680 shares of the company’s stock, valued at $870,883.20. The disclosure for this purchase can be found here. 4.50% of the stock is owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. Raymond James & Associates increased its position in Arrowhead Pharmaceuticals by 47.8% in the third quarter. Raymond James & Associates now owns 28,343 shares of the biotechnology company’s stock worth $762,000 after buying an additional 9,167 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Arrowhead Pharmaceuticals by 8.6% during the third quarter. Victory Capital Management Inc. now owns 48,948 shares of the biotechnology company’s stock worth $1,315,000 after purchasing an additional 3,890 shares in the last quarter. Fox Run Management L.L.C. grew its position in shares of Arrowhead Pharmaceuticals by 34.0% during the third quarter. Fox Run Management L.L.C. now owns 11,780 shares of the biotechnology company’s stock worth $317,000 after purchasing an additional 2,988 shares in the last quarter. New York State Common Retirement Fund grew its position in shares of Arrowhead Pharmaceuticals by 2.4% during the third quarter. New York State Common Retirement Fund now owns 42,866 shares of the biotechnology company’s stock worth $1,152,000 after purchasing an additional 999 shares in the last quarter. Finally, Moody Aldrich Partners LLC boosted its stake in Arrowhead Pharmaceuticals by 3.7% during the third quarter. Moody Aldrich Partners LLC now owns 59,669 shares of the biotechnology company’s stock valued at $1,603,000 after buying an additional 2,134 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ:ARWR opened at $22.78 on Friday. Arrowhead Pharmaceuticals has a twelve month low of $20.67 and a twelve month high of $39.83. The stock’s 50 day moving average is $24.76 and its 200-day moving average is $28.52. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -5.36 and a beta of 0.78.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Free Report) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same period in the previous year, the business earned $0.45 EPS. The company’s revenue for the quarter was down 100.0% compared to the same quarter last year. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -3.05 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Further Reading

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.